You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(2196.HK)高開近15% 擬與BioNTech設合資公司 實現mRNA疫苗本地化生產及商業化
格隆匯 05-10 09:23
格隆匯5月10日丨復星醫藥(2196.HK)跳空高開14.99%報57.55港元,最新市值1638億港元。公司5月9日宣佈,控股子公司復星醫藥產業擬與BioNTech設立合資公司,以實現mRNA新冠疫苗產品的本地化生產及商業化。雙方將分別認繳合資公司註冊資本的50%。其中,復星醫藥產業擬以現金及/或有形或無形資產作價出資合計不超過1億美元、BioNTech擬以其相關生產技術和專有技術許可等無形資產作價出資合計不超過1億美元。早在去年3月,復星醫藥與BioNtech簽訂mRNA新冠疫苗的許可協議,獲授權在大中華區(中國大陸及港澳台)獨家開發、商業化基於後者專有的mRNA技術平台研發的、針對新型冠狀病毒的疫苗產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account